Scientific Program | IMS 2020

Scientific Program


More sessions and speakers will be announced soon

Views Filters
  • By Session
  • Timetable
  • Program
  • Posters
  • Sponsored symposia
  • By speaker
  • Speakers
  • Tracks
  • Print

Plenary Lecture

  • Bio Identical hormones and alternative options; where (why) have we failed?

    • Rodney Baber Bio Identical hormones and alternative options; where (why) have we failed?
  • Dementia

    • Roberta Brinton Diaz Early Detection of Alzheimer's Risk to Reverse Course and Save a Brain
  • Do we need nutritional supplementation for healthy aging?

    • Ian Reid Do we need nutritional supplementation for healthy aging?
  • Early detection and better survival of cancer patients in South East Asian women

    • Teo Soo Hwang Early detection and better survival of cancer patients in South East Asian women
  • How to prepare for the best years of your life: a global perspective

    • Islene Araujo de Carvalho How to prepare for the best years of your life: a global perspective
  • Nanotechnology and Nanomedicine, allowing an engineered approach to the treatment of cancer

    • Ander Nel Nanotechnology and Nanomedicine, allowing an engineered approach to the treatment of cancer
  • Pieter Van Keep lecture

    • Susan Davis Pieter Van Keep lecture
  • Social determinants of health- the social cure

    • Jolanda Jetten Social determinants of health- the social cure
  • Sonia's Snippets; an update on the latest and greatest in themenopause world

    • Sonia Davison Sonia's Snippets; an update on the latest and greatest in the menopause world

Symposium

  • A matter of the mind: sex steroids and the brain

    • Roberta Brinton Diaz Immune system; driver of menopausal brainenergy system
    • Herman Depypere Sex steroid hormones and brain function
    • Pauline Maki Cognition and menopause; the role of sleep and hot flushes
  • Bad bones break

    • Ian Reid Target to treat: who should be treated
    • Peter Ebeling Treat to target: when to stop
    • Manju Chandran The treatment gap. Why do we miss the target
  • Beat the heat

    • Julie Prague NK3 inhibitors - prime time?
    • Martha Hickey Managing vasomotor symptoms effectively without hormones
    • Qi Yu Traditional/alternative remedies for VMS
  • Caring for specific populations

    • Amanda Vincent Menopausal Hormone therapy and primary ovarian insufficiency
    • Jayashri Kulkarni Depression and MHT
    • Paulina Villaseca BRCA surveillance, intervention and MHT
  • Does the picture tell the story?

    • Sonia Cerdas Bone imaging in clinical practice
    • Steven Goldstein Ultrasound and the menopausal endometrium
    • Tony Miller Imaging the breast, when and how?
  • Ethical issues

    • James Pickar Ethics in Publishing
    • Penny Browne When is it a good time to retire
  • Laser: turning up the heat; revolution or hazard

    • Marco Gambacciani The nuts and bolts; how does Laser work
    • Jason Abbott The evidence
    • Tim Hillard Setting standards for laser use in Gynaecology
  • Matters of the heart

    • Gemma Figtree A female-centric approach to preventing heart disease
    • Virginia Miller Lessons from KEEPS
    • Peter Chedraui Preventing cardiometabolic disease
  • Negotiating with mother nature and father time; strategies to facilitate successful aging

    • Sunila Khandelwal The role of diet
    • Seng Bin Ang The role of exercise
    • Robert Langer MHT and mortality
  • Sexy after sixty

    • Jan Shifren Time marches on – impact of aging on sexuality
    • Rossella Nappi I get by with the help of my friends; therapeutic options for women
    • Rosie King I get by with the help of my friends; therapeutic options for men
  • When Everything falls - optimising pelvic floor management

    • Tommaso Simoncini Menopause, aging and the failing pelvic floor: a clinician’s view
    • Tomi Mikkola Treatment of urinary incontinence; to mesh or not
    • Ivan Fistonic The use of laser in uro-gynaecology - a review of the evidence

Debate

  • Estrogen as first line therapy for prevention and treatment of osteoporosis

    • Florence Tremollieres
    • Peter Ebeling
  • Is there a role for androgen therapy beyond sexuality

    • Susan Davis
  • MHT for primary prevention

    • Robert Langer
    • Mary Ann Lumsden
  • Will NK3 inhibitors replace MHT as first choice in the treatment of VMS?

    • Julie Prague
    • JoAnn Pinkerton

Meet the Experts

  • Care of survivors of menopausal cancers

    • JoAnn Pinkerton
  • Complementary therapies and other alternatives to HT - when and how?

    • Nick Panay
  • Innoculations

    • Vivien Brown
  • Management of POI

    • Stephanie Faubion
  • Sex Steroids and Depression Across the Lifespan of Women

    • Andrea Genazzani
  • Understanding gene mutations and breast cancer

    • Kelly Anne Phillips
  • When to start/stop bone-specific medication

    • Manju Chandran

Meet the Panel

  • Common gynaecological problems in peri/post menopausal women

    • Wendy Wolfman
    • Mary Ann Lumsden
    • David Archer
    • Xiangyan Ruan
    • Steven Goldstein
  • How to conduct a menopause clinical visit; what should be done and discussed

    • Camilo Rueda
    • Bronwyn Stuckey
    • Tevfik Yoldemir
    • Serge Rozenberg
    • Nasreen Zinnat

Symposium organized by CAMS Societies

  • Approach of climaterio for the XXI century in latin america, in patients with special situations (FLASCYM)

    • Paulina Villaseca Approach of the Sx. climacteric in surviving patients Ca Mama
    • Luis Danckers Schemes of TH in climacteric patients with Diabetes and / or Metabolic Sx
    • Konstantinos Tserotas Schemes of TH; risks and benefits, in climacteric patients with autoimmune diseases
  • Asia Pacific Menopause Federation

  • Asociacion Colombiana de Menopausia

  • Australasian Menopause society

  • Bangladesh Menopause Society

  • Breast cancer risk and hormones (Germany/Switzerland)

    • Petra Stute Impact of progestogen type in MHT on breast cancer risk
    • Alfred Mueck PGRMC1 in breast cancer development and prediction of prognosis
    • Ludwig Kiesel Hormone resistance and breast cancer
  • British Menopause Society

    • Haitham Hamoda Androgens and the postmenopausal woman
    • Nick Panay Progesterones in HRT - choice of preparation and its impact
    • John Stevenson MHT for the primary prevention of cardiovascular disease - Are we there yet?
  • European Menopause and Andropause Society

  • European Society of Gynecology

  • Healthy Aging - New Frontiers in Compressing Co morbidities (Indian Menopause Society)

    • Maninder Ahuja Chronological and biological aging Cellular and molecular basis
    • Neelam Aggarwal Gut microbiomes
    • Pratibha Singh No to breaking Bones
    • Pushpa Sethi Slow down hands of time- Exercise and diet
    • S.P Jaiswar Cancer screening in India is not lagging
    • Anju Soni Face lift of pelvic floor - Our gateway
  • International Society of Gynecological Edocrinology

  • Korean Society of Menopause

  • North American Menopause Society

  • Perkumpulan Menopause Indonesia

  • Quality of life and longevity after menopause (Russian Menopause Society)

    • Vera Balan Aging, anti-aging and ageism
    • Elena Andreeva Menopausal hormone therapy as a marker of longevity
    • Svetlana Yureneva Treatment of vaginal symptoms and VVA in postmenopausal women: why Estriol-Lactobacilli combination is preferable?
    • Antonina Smetnik Sex steroids, breast and breast cancer.
  • Thinking about the health care of women during the climacteric (AAPEC)

    Chairperson/s: Graciela Lopez de Degani , Mariana Degani

    • Claudia Rey Should the peri and postmenopausal women always be treated?
    • Rita Caro Abnormal uterine bleeding in the perimenopause
    • Blanca Campostrini Choosing the best options for the treatment of symptomatic climacteric
    • Olga Marega Treated Dyspareunia means assured Sexual Satisfaction?
    • Seybold Barbara Discussion 
    • Freijedo Valeria Discussion
    • Cristina Toha Discussion

Pre-Congress Course

  • Menopause Essentials

    • Delfin Tan Menopause: What is it?
    • Rodney Baber Prescribing MHT
    • Anna Fenton Other options
    • JoAnn Pinkerton Disorders Downunder: Evaluation and management

 

The views expressed by sponsors, exhibitors or attendees at the World Congress are not necessarily the views of the International Menopause Society (IMS), and the Society does not accept responsibility for or recommend any products, information, research, recommendations or advice contained herein.

This site uses cookies for functional and analytical purposes. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. More info about cookies

Close